RxDoctor Payments DataLook up a doctor →

Christopher Vachon

Neurology · Fort Wayne, INNPI 1316366735

Payments from drug & device makers

$114,370in general payments, 2019–2025

Across 584 payments — averaging $195.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Pharma SAS$87K
  • AbbVie$20K
  • Argenx US, Inc.$3K
  • Biogen$354
  • UCB, Inc.$353
  • Biohaven Pharmaceuticals, Inc.$343
  • plus $3K from 42 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$18,97570%
  • Travel & lodging$1,2295%
  • Food & beverage$6,84225%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,370 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$53,672
Medicare patients
230
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone37$546,275
WakixPitolisant Hcl11$179,230
QuliptaAtogepant61$72,556
UbrelvyUbrogepant49$68,732
Emgality PenGalcanezumab-Gnlm77$60,142
GocovriAmantadine Hcl14$47,957
FingolimodFingolimod Hcl22$28,217
Nurtec OdtRimegepant Sulfate16$24,886
Lacosamide32$9,104
Pyridostigmine Bromide62$8,825
Pyridostigmine Bromide ErPyridostigmine Bromide15$8,753
Riluzole39$6,636
Carbidopa-LevodopaCarbidopa/Levodopa171$4,757
Mycophenolate Mofetil37$3,625
Carbidopa-Levodopa ErCarbidopa/Levodopa64$2,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$29$179,23011 claims
AbbVieQulipta, Ubrelvy$20,219$141,288110 claims
MDD US Operations, LLCGocovri$13$47,95714 claims
PfizerNurtec Odt$110$24,88616 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$52$12,45099 claims
Upsher-smith Laboratories LLCTopiramate$58$7915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →